RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
RenovoRx, Inc.NASDAQ: RNXT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 14.4% from a year ago
Total equity stood at $11.27M at the end of Q1 FY2026, down 14.4% from a year earlier and up 107.8% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.
Context
- Total equity amounted to 80.7% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -14.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 5.42M USD
- Year-over-year change
- +21.1%
- 4-year CAGR
- -22.9%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.42M | +21.1% |
| FY2024 | 2024-12-31 | 4.48M | +249.3% |
| FY2023 | 2023-12-31 | (3M) | -148.7% |
| FY2022 | 2022-12-31 | 6.16M | -59.8% |
| FY2021 | 2021-12-31 | 15.35M | — |
Total Equity vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total equity of $11.27M is the 2nd highest of the 6 companies compared; the peer median is $3.45M.
- Its year-over-year change of -14.4% is the 3rd highest of 6, against a peer median of -79.5%.
- Total equity amounts to 80.7% of total assets for RNXT, versus a peer median of 45.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $27.76M | +461.7% | -34.6% | 78.6% | |
| Mar 2026 | $11.27M | -14.4% | -4.2% | 80.7% | |
| Mar 2026 | $8.78M | +10109.3% | +23.5% | 45.8% | |
| Mar 2026 | $3.45M | -79.5% | +388.5% | 47.7% | |
| Mar 2026 | $3.13M | -87.0% | -15.9% | 19.2% | |
| Dec 2025 | -$38.06M | -530.7% | — | 35.5% | |
| Peer median (excluding RNXT) | $3.45M | -79.5% | +3.8% | 45.8% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.